Tagged Articles

pancreatitis 53 articles

New warnings added to IBS drug Viberzi

The Food and Drug Administration (FDA) has updated the safety label for the irritable bowel syndrome (IBS) medication Viberzi (eluxadoline) to include new warnings regarding pancreatitis and sphincter of Oddi spasm, a loss of normal function of the smooth muscle that surrounds the end portion of the common bile duct and pancreatic duct, which can cause obstruction of bile flow and obstruction to the flow of pancreatic juice into the intestine. The label now discourages use of the IBS drug in patients without a gallbladder because they are at increased risk of developing serious adverse reactions of pancreatitis and/or sphincter ... Read More

IBS drug possibly linked to sphincter of Oddi dysfunction, pancreatitis

Some patients taking the irritable bowel syndrome (IBS) treatment Viberzi have developed a painful gastrointestinal disorder known as sphincter of Oddi dysfunction that has led to cases of pancreatitis, according to the Food and Drug Administration (FDA) quarterly (July-September 2016) report Potential Signals of Serious Risks/New Safety Information, which are identified by the FDA Adverse Event Reporting System (FAERS). The serious side effects identified by the report are evaluated by the FDA to determine if further regulatory action is needed, such as changes to the drug’s label, the development of a Risk Evaluation and Mitigation Strategy (REMS), or further information ... Read More

Type 2 diabetics at greater risk of developing pancreatic, liver cancers

People with type 2 diabetes who were hospitalized at some point to treat their disease are at an increased risk of developing certain types of cancer, a new study has found. Researchers at Lund University in Sweden; Germany Cancer Research Center in Heidelberg, Germany; and Stanford University in California analyzed data from a national Swedish database and found type 2 diabetics were more likely to have cancer. The most common cancers among these patients affected the colon, liver, pancreas, endometrium, and kidney. The risk for pancreatic cancer and liver cancer in these patients was particularly high, the researchers noted. Pancreatic ... Read More

Victoza fails to improve health in heart failure patients

Novo Nordisk has made great strides to expand the indication of its type 2 diabetes drug Victoza by gaining approval for a high-dose version as a weight loss treatment, marketed as Saxenda. The company is also testing the drug as a treatment for nonalcoholic fatty liver disease. But a new study found the drug ineffective in patients with advanced heart failure. Heart failure is a chronic condition in which the heart does not pump enough blood through the body. About 5 million Americans have heart failure. The study sought to find whether Victoza, known chemically as liraglutide, could correct defects in ... Read More

Victoza studied in obese patients with pre-diabetes

People who are obese and pre-diabetic can lose weight and delay the onset of type 2 diabetes by more than three years if they take a newer diabetes medication, according to a study presented at ObesityWeek 2015. However, the medication puts users at risk for dangerous side effects. The study involved the type 2 diabetes drug liraglutide, known by the brand name Victoza, which was approved by the Food and Drug Administration (FDA) in 2010. In December 2014, the agency approved a higher dose of the drug, marketed as Saxenda, for weight loss in obese non-diabetics, and for overweight patients ... Read More

Four Dangerous Diabetes Drugs

Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More

Study raises concerns about class of type 2 diabetes drugs

A class of type 2 diabetes drugs used to reduce blood sugar levels may actually promote the release of sugars into the blood, according to a paper published in the Journal of Biological Chemistry. The class of drugs is known as GLP-1 agonists, which includes the brand names Byetta (exenatide) and Victoza (liraglutide), which were made available in the United States in 2005 and 2010, respectively. According to Doctor Tipster, GLP-1 agonists work by imitating the effects of a naturally occurring hormone, called a glucagon-like peptide. This regulates blood sugar levels by stimulating the release of insulin and by inhibiting ... Read More

AstraZeneca diabetes drug cocktail rejected by FDA

The Food and Drug Administration (FDA) rejected a fixed-dose drug cocktail from AstraZeneca to treat type 2 diabetes, saying not enough clinical data was provided with the drug’s application. AstraZeneca took the news hard, saying the setback would push back the drug’s launch date by a year or two, depending on whether new clinical trials would need to be conducted. The drug is a combination of two already FDA-approved drugs to treat type 2 diabetes – saxagliptin and dapagliflozin. Saxagliptin, which is sold under the brand name Onglyza, is a class of diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, ... Read More

Study questions sugar spike risk with diabetes drugs Byetta, Victoza

A class of drugs designed to regulate blood sugar levels in type 2 diabetics may actually trigger spikes in blood sugar levels, potentially causing more harm than good, a new study shows. The research, published in the Journal of Biological Chemistry, involved a class of drugs called GLP-1 agonists, which include the brand name drugs Byetta and Victoza. The medications work by stimulating the release of insulin by the pancreas after eating, and slowing glucose absorption in the bloodstream by reducing the speed at which the stomach empties after eating, making users feel more satisfied after a meal. However, GLP-1 ... Read More

Researchers eye diabetes drugs as possible alcohol addition treatment

A class of type 2 diabetes drugs, which includes the brand names Victoza and Byetta, may help curb alcohol addiction and could pave the way for wider usage of the medications, according to a new study. However, it could also expose more people to potentially deadly side effects. Victoza and Byetta are in a class of drugs known as GLP-1 agonists. They work by mimicking the functions of the natural incretin hormones in the body that help lower post-meal blood sugar levels. These functions include stimulating the release of insulin by the pancreas after eating, inhibiting the release of glucagon ... Read More